Clinical Trials · NCT07428525

A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

Name: A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Maridebart cafraglutide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Amgen
Enrollment: 36
Start date: Mar 2025
Locations: 5 sites, United States
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AMG 133

View Maridebart-Cafraglutide compound reference